- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01872455
Diet Rich in N-3 Polyunsaturated Fatty Acids in Renal Transplant Recipients
EFFECTS OF A DIET RICH IN N-3 POLYUNSATURATED FATTY ACIDS ON SYSTEMIC INFLAMMATION IN RENAL TRANSPLANT RECIPIENTS
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
An emerging concept in clinical nutrition is that dietary interventions may improve the course of systemic inflammatory disorders like rheumatoid arthritis and psoriasis. Most of this effect depends on the ability of polyunsaturated fatty acids (PUFAs) to modulate immune and inflammatory responses. Two main families of PUFAs exist in human tissues: n-3 PUFAs that have a marked anti-inflammatory activity and n-6 PUFAs that, conversely, promote inflammation. Multiple mechanisms account for the modulation of the inflammatory response by PUFAs. Recent lipidemic studies have added new mediators like lipoxins to the list of PUFA metabolites controlling inflammation that classically included only pro-inflammatory or anti-inflammatory prostaglandins like PGE2 and PGE3, respectively. The concerted activity of these mediators may determine a decreased recruitment of inflammatory cells in target tissues, with a lower release of pro-inflammatory cytokines like Interleukin-6 (IL-6) and necrosis tumor factor-α (TNF), and their higher apoptosis rate.
n-3 PUFAs include α-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), whereas linoleic acid (LA) and arachidonic acid (AA) are the main n-6 PUFAs. ALA and LA are both essential fatty acids because they cannot be synthetized in the human body and have to be assumed with the diet. They are the precursors of downstream immunomodulatory long-chain fatty acids: LA is converted to AA that has marked a pro-inflammatory activity and is further transformed in pro-inflammatory eicosanoids (PGE2) and leukotrienes. On the contrary, ALA is converted to EPA and DHA, the precursors of anti-inflammatory prostaglandins (PGE3) and inhibits the production of AA and the synthesis of thromboxane. Importantly, the amount of ALA converted to EPA and DHA in humans is usually low which makes also these fatty acids essential. The current western diet is poor of n-3 PUFAs and this suggests that n-3 PUFAs-dependent endogenous anti-inflammatory mechanisms could be potentiated by simultaneously increasing n-3 PUFA intake and lowering the n-6/n-3 ratio. Indeed, a high n-6/n-3 ratio is associated to a worse clinical course in cardiovascular, inflammatory and autoimmune diseases. With the rationale of increasing n-3 PUFAs intake and of lowering the n-6/n-3 ratio, n-3 PUFAs supplementations like fish oil have been given with favorable clinical results to patients affected by different chronic inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Fish oil, however, has a low palatability and this may cause a low patients' compliance during prolonged therapy. Since seafood, and several fruits and vegetables have a high content of n-3 PUFAs, dietary regimens based on these specific foods are expected to increase n-3 PUFAs intake., thus representing an attractive alternative to the administration of exogenous fish oils products in therapeutic programs aimed to exploit the beneficial n-3 PUFAs effects in systemic inflammatory disorders.
Therefore, the investigators explored the effect of a diet based on food with a high n-3 and low n-6 PUFAs content in long-term kidney transplant recipients. These patients could benefit from an increase in n-3 PUFAs intake because a persistent systemic inflammatory status occurs after kidney transplantation, that greatly contributes to the development of cardiovascular diseases and of chronic allograft dysfunction. Previous studies showed that dietary administration of n-3 increases graft survival in different animal models of organ transplantation, whereas n-6 PUFAs had opposite effects. Recently, the efficacy of n-3 PUFAs supplementation with canola oil in decreasing systemic inflammation and in lowering the incidence of rejections was demonstrated also in humans.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Naples, Italy, 80131
- federico II Univeristy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age >18 years,
- transplant vintage >12 months,
- a preserved and stable renal function (eGFR>20 ml/min),
- plasma urea concentration <150 mg/dl,
- plasma albumin concentration >3.8 g/dl,
- and a stable protein and salt intake (±15%) in the last two visits
Exclusion Criteria:
- malignancies,
- autoimmune diseases
- and severe infectious diseases in the last three months before the enrollment visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Group CON
patients who refused to assume the n-3 rich diet and continued their usual diet
|
Usual diet of the patients
|
|
Experimental: Group DIET
the patients assumed n-3 rich diet: Patients of the DIET group were requested to follow a diet specifically designed to increase the intake of n-3 PUFAs and to decrease the ratio n-6/n-3 by using natural foods.
|
This dietary plan included seafood (salmon, sardines, herrings, and bluefish) and specific fruits and vegetables (oranges, strawberries, cherries, bananas, courgettes, artichokes, mushrooms, cauliflowers and pumpkins).
Olive oil, rich in monounsaturated fats, was also included in the dietary plan.
Patients were encouraged to use n-3 rich margarine as additional source of fatty acids.
According to the data of the manufacturer, the fatty acid composition of this margarine was 3.4 mg of n-3 and 7.8 mg of n-6 per 100 g of weight.
To keep n-6 PUFA intake low, patients were also requested to eat less eggs, meat, whole grains and cereals.
All the components of the diet were fresh foods, with the exception of salmon and herrings that could also be preserved.
Because no change in body weight was requested, patients maintained the same energy and protein intake of the diet that they assumed before entering the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nutritional assessment
Time Frame: 6 months
|
Anthropometric, body composition, biochemical, dietary and inflammatory parameters were recorded in all patients participating to the study, at baseline and three and six months after the start of the protocol.
Body mass index (BMI) was calculated as the ratio body weight/height2 (in kg/m2) whereas bioelectrical impedance analysis (BIA) was used to evaluate body composition.
Resistance and reactance were measured with a single-frequency 50 kHz bioelectrical impedance analyser, according to the standard tetrapolar technique and using the software provided by the manufacturer.
|
6 months
|
|
Inflammatory markers
Time Frame: 6 months of diet
|
Biochemical nutritional markers included standard blood chemicals like serum albumin, urea nitrogen, glycemia and electrolytes, whereas fibrinogen, ferritin, Interleukin-6 (IL-6), and high sensitivity C Reactive Protein (hs-CRP) were assessed as markers of inflammation.
IL-6 messenger ribonucleic acid (mRNA) levels were also determined in peripheral blood mononuclear cells (PBMC) at baseline and three and six months after beginning of the study.
|
6 months of diet
|
|
renal function
Time Frame: 6 months of diet
|
Renal allograft function was evaluated by Glomerular Filtration Rate (GFR), proteinuria, and microalbuminuria; GFR was calculated by the 4-variable Modification of Diet in Renal Disease (MDRD) equation (eGFR).
Urinary determinations were carried out on samples collected for 24 hours.
|
6 months of diet
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- TX13
- TX (Other Identifier: Ethic commettee)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Bristol-Myers SquibbCompletedKidney Transplantation: Transplantation, Kidney
-
Hospices Civils de LyonCompletedKidney Transplantation | Pancreas-kidney TransplantationFrance
-
Nantes University HospitalTerminated
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Medical University of ViennaUnknownKidney Function After Transplantation | Outcome After Kidney Transplantation
Clinical Trials on Usual diet
-
Brigham and Women's HospitalUniversity of Illinois at Urbana-Champaign; American Pistachio Growers; Quest... and other collaboratorsActive, not recruitingCognition | Life Satisfaction | Cardiometabolic Risk FactorsUnited States
-
Pennington Biomedical Research CenterCompletedBody Weight | Insulin ResistanceUnited States
-
University College CorkCompletedElevated Blood PressureIreland
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Purdue UniversityJohns Hopkins University; University of California, San Diego; National Heart... and other collaboratorsTerminated
-
Stanford UniversityNot yet recruitingSchizophrenia | Metabolic Syndrome | Bipolar Disorder | Bipolar and Related Disorders | Major Depressive Disorder | Ketosis | Schizophrenia and Related Disorders | Metabolic Disease | Ketogenic Dieting | Major Depression SevereUnited States
-
Hospital Authority, Hong KongUnknownDiabetes MellitusChina
-
University of VirginiaCompletedObesity | Food Preferences | Hunger | Ingestive BehaviorUnited States
-
Nutrisystem, Inc.University of PennsylvaniaUnknown
-
Stanford UniversityCompletedInflammation | Cancer | Microbiome | Immune FunctionUnited States